|
|
|
Volumn 40, Issue 2, 2007, Pages 41-53
|
|
Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ASENAPINE;
BENZODIAZEPINE DERIVATIVE;
FUSED HETEROCYCLIC RINGS;
NEUROLEPTIC AGENT;
OLANZAPINE;
ADULT;
ARTICLE;
BIOASSAY;
COMPARATIVE STUDY;
DEPRESSION;
DOSE RESPONSE;
DYSKINESIA;
FEMALE;
HUMAN;
MALE;
METHODOLOGY;
MIDDLE AGED;
MULTICENTER STUDY;
NEUROLOGIC EXAMINATION;
PATIENT SELECTION;
PHASE 3 CLINICAL TRIAL;
PSYCHOLOGICAL ASPECT;
PSYCHOLOGICAL RATING SCALE;
PSYCHOLOGY;
RANDOMIZED CONTROLLED TRIAL;
SCHIZOPHRENIA;
TREATMENT OUTCOME;
ADULT;
ANTIPSYCHOTIC AGENTS;
BENZODIAZEPINES;
CLINICAL TRIALS, PHASE III;
DEPRESSIVE DISORDER;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DYSKINESIA, DRUG-INDUCED;
ENDPOINT DETERMINATION;
FEMALE;
HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS;
HUMANS;
MALE;
MIDDLE AGED;
MULTICENTER STUDIES;
NEUROLOGIC EXAMINATION;
PATIENT SELECTION;
PSYCHIATRIC STATUS RATING SCALES;
RANDOMIZED CONTROLLED TRIALS;
RESEARCH DESIGN;
SCHIZOPHRENIA;
SCHIZOPHRENIC PSYCHOLOGY;
TREATMENT OUTCOME;
|
|
EID: 34548565709
PISSN: 00485764
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (31)
|
|
References (0)
|
